Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.

IF 2.6 4区 医学 Q2 CLINICAL NEUROLOGY
Diego Santos-García, Ángela Solleiro, Guillermo González-Ortega, Pablo Mir, Nuria López-Ariztegui, Rocío García Ramos, Inés Legarda, Anna Planas-Ballvé, Deborah Alonso-Modino, Pilar Sánchez-Alonso, Iria Cabo, Marta Blázquez-Estrada, Álvaro Sánchez-Ferro
{"title":"Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.","authors":"Diego Santos-García, Ángela Solleiro, Guillermo González-Ortega, Pablo Mir, Nuria López-Ariztegui, Rocío García Ramos, Inés Legarda, Anna Planas-Ballvé, Deborah Alonso-Modino, Pilar Sánchez-Alonso, Iria Cabo, Marta Blázquez-Estrada, Álvaro Sánchez-Ferro","doi":"10.1002/mdc3.70239","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024.</p><p><strong>Patients and methods: </strong>Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.</p><p><strong>Results: </strong>A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.</p><p><strong>Conclusion: </strong>Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.70239","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024.

Patients and methods: Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.

Results: A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.

Conclusion: Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.

在西班牙用器械辅助疗法治疗帕金森病患者的概况一项多中心比较观察研究。
背景和目的:新的设备辅助疗法(dat)已经出现,用于治疗帕金森病(PwP)。我们的目的是了解哪些dat是由神经科医生指示的,并比较2024年西班牙在实际临床实践中接受治疗的患者的特征。患者和方法:数据收集于dat - pd GETM西班牙注册中心(REDCap)。这是一项描述性的、观察性的、前瞻性的、多中心的临床登记,在西班牙40多个中心进行了10年的日常临床实践条件下,逐步纳入了使用DAT治疗的PwP。本研究只分析了第1次就诊的数据(DAT指示),未分析随访数据。所有在2024年12月31日之前接受过DAT信息的患者都被纳入研究。结果:共313例PD患者(66.7±9.6岁;61.7%男性)接受了DAT治疗。最常见的DAT是皮下foslevodopa/foscarbidopa (fLD/fCD)(47%),其次是脑深部刺激(DBS)(20.1%)和持续皮下阿波啡输注(CSAI)(19.8%)。高达23.6%的患者至少接受过一次DAT治疗,47%的患者接受过按需治疗。在不同的DAT组之间观察到年龄、波动时间和其他方面(运动状态、生活质量或日常生活活动等)的差异。具体来说,接受DBS治疗的患者更年轻,病情更轻,而接受LECIG治疗的患者受影响最大。结论:2024年西班牙实施的DATs中,皮下治疗和DBS是最常见的(86.9%)。在DAT类型之间检测到配置文件差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
7.50%
发文量
218
期刊介绍: Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信